Inclusion Criteria:

- Histologically or cytologically confirmed advanced and/or aggressive hematologic
malignancy (including myelodysplastic syndrome) that is unlikely to be cured by
alternative therapies

- HLA-Matched unrelated donor; or 1-locus HLA-mismatched related or unrelated donor

- ECOG performance status 0-2

- Adequate organ function

- Able to understand and willing to sign a written informed consent document

- Agrees to practice adequate contraception per study requirements

Exclusion Criteria:

- Pregnant or breastfeeding

- Recipient of prior allogeneic or autologous stem cell transplantation

- Prior abdominal radiation therapy

- HIV-positive on combination antiretroviral therapy

- Seropositive for hepatitis B or C

- Allergies to bortezomib, boron, or mannitol

- Myocardial infarction within last 6 months, NYHA Class III or IV heart failure,
uncontrolled angina, severe uncontrolled ventricular arrhythmias

- Uncontrolled bacterial, viral or fungal infections

- Seizures or history of seizures

- History of another non-hematologic malignancy unless disease-free for at least 5
years

- Uncontrolled intercurrent illness